Dymista Nasal Spray

DRUG2 trials

Sponsors

Meda Pharmaceuticals, Glenmark Pharmaceuticals Ltd. India

Conditions

Allergic RhinitisSeasonal Allergic Rhinitis

Phase 2

Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)

CompletedNCT03444506

Glenmark Pharmaceuticals Ltd. IndiaSeasonal Allergic Rhinitis

Start: 2014-01-27End: 2014-02-28Updated: 2018-06-20

Phase 3

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

CompletedNCT01794741

Meda PharmaceuticalsAllergic Rhinitis

Start: 2013-02-28Updated: 2015-03-31

Related Papers

Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study.

2018-10-1228 citations

Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial

Allergy and Asthma Proceedings2018-03-0126 citations